Literature DB >> 11597941

Insulin inhibits the maturation phase of VLDL assembly via a phosphoinositide 3-kinase-mediated event.

A M Brown1, G F Gibbons.   

Abstract

LY 294002 (80 micromol/L), an inhibitor of phosphoinositide 3-kinase, was used to investigate the involvement of this enzyme in the insulin-mediated regulation of very low density lipoprotein (VLDL) apolipoprotein B (apoB) output from cultured rat hepatocytes. Newly synthesized apoB was pulse-labeled with [(35)S]methionine and was then allowed to assemble, via an intermediate precursor stage, into mature VLDL during subsequent chase periods. Brefeldin A (BFA, 0.2 microgram/mL) was used to discriminate between the role of insulin in the regulation of the early, compared with the later, events of VLDL assembly, including apoB degradation. Insulin (78 nmol/L), when present during the pulse-labeling and subsequent chase periods, inhibited the secretion of apoB-100 and apoB-48 as VLDL by 53% and 56%, respectively. Degradation of both was concomitantly increased. Secretion of high density lipoprotein apoB, derived from VLDL precursors, was relatively unaffected under these conditions, as was the net synthesis of apoB-100 and apoB-48. The presence of BFA during the pulse-labeling period and subsequent chase period prevented the maturation of VLDL in the insulin-treated and the non-insulin-treated cells. BFA was then removed, allowing the maturation of VLDL to proceed. Removal of insulin at this stage reversed the overall inhibitory effect of insulin. Furthermore, when insulin remained present during this period, the simultaneous presence of LY 294002 also reversed the inhibitory effect of insulin on VLDL apoB output and abolished the increase in apoB degradation. The results suggest that insulin signaling via phosphoinositide 3-kinase inhibited the maturation phase of VLDL assembly by preventing bulk lipid transfer to a VLDL precursor, thus enhancing the degradation of apoB. There was no inhibition of the conversion of newly synthesized apoB into the VLDL precursor form.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11597941     DOI: 10.1161/hq1001.096640

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

Review 1.  The roles of insulin and fatty acids in the regulation of hepatic very-low-density lipoprotein assembly.

Authors:  G F Gibbons; A M Brown; D Wiggins; R Pease
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  Hepatic ABCA1 and VLDL triglyceride production.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta       Date:  2011-10-06

Review 3.  Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Authors:  Sung Hee Choi; Henry N Ginsberg
Journal:  Trends Endocrinol Metab       Date:  2011-05-26       Impact factor: 12.015

4.  A novel role for ABCA1-generated large pre-beta migrating nascent HDL in the regulation of hepatic VLDL triglyceride secretion.

Authors:  Soonkyu Chung; Abraham K Gebre; Jeongmin Seo; Gregory S Shelness; John S Parks
Journal:  J Lipid Res       Date:  2010-04       Impact factor: 5.922

5.  Hepatic ABCA1 deficiency is associated with delayed apolipoprotein B secretory trafficking and augmented VLDL triglyceride secretion.

Authors:  Mingxia Liu; Soonkyu Chung; Gregory S Shelness; John S Parks
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-07-08       Impact factor: 4.698

Review 6.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting.

Authors:  Jeffrey M Chamberlain; Colleen O'Dell; Charles E Sparks; Janet D Sparks
Journal:  Biochem Biophys Res Commun       Date:  2012-11-15       Impact factor: 3.575

8.  Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.

Authors:  Emma M Allister; Erin E Mulvihill; P Hugh R Barrett; Jane Y Edwards; Lindsey P Carter; Murray W Huff
Journal:  J Lipid Res       Date:  2008-06-27       Impact factor: 5.922

Review 9.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

10.  Insulin-dependent apolipoprotein B degradation is mediated by autophagy and involves class I and class III phosphatidylinositide 3-kinases.

Authors:  Janet D Sparks; Colleen O'Dell; Jeffrey M Chamberlain; Charles E Sparks
Journal:  Biochem Biophys Res Commun       Date:  2013-05-15       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.